disability progression

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: Insights from the OPERA I and II Randomized Clinical Trials and Related Evidence

By MedXY 10/10/2026

Continuous ocrelizumab treatment over 10 years in relapsing MS significantly delays disability progression, reduces relapse rates, and maintains a favorable safety profile, underscoring the clinical benefit of early high-efficacy therapy.

Neurology news

Paramagnetic Rim Lesions as Predictors of Progression in Multiple Sclerosis: Insights from a 5-Year Longitudinal Study

By MedXY 08/22/2026

Paramagnetic rim lesions detected via MRI are associated with increased risk of disability progression independent of relapse activity and accelerated brain atrophy in multiple sclerosis, highlighting their role as prognostic biomarkers for risk stratification.

Allergy & Immunology Clinical Updates news OB/GYN & Women's Health Specialties

Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression

By MedXY 09/29/2025

A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging's role in disease trajectory.

Allergy & Immunology Clinical Updates OB/GYN & Women's Health

Pregnancy and Disease Outcomes in Women with Moderate to Severe Multiple Sclerosis Disability

By MedXY 09/24/2025

This study evaluates how pregnancy affects relapse rates and long-term disability in women with moderate to severe multiple sclerosis (MS), showing pregnancy reduces relapse during gestation without worsening long-term disability progression.